Regulatory document
PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk…
EMA · Information · EU · Oct 27, 2017
Key facts
| Title | PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage |
|---|---|
| Issuer | European Medicines Agency |
| Source | EMA |
| Document type | Information |
| Country or region | EU |
| Date | Oct 27, 2017 |
| Document | ema.europa.eu |
| Issuer website | ema.europa.eu |
At a glance
- Yes Full text searchable in Orca1
- 1,000+ Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: